Intense lipid peroxidation in premature clinical coronary atherosclerosis is associated with metabolic abnormalities

Journal of Laboratory and Clinical Medicine

Volumn 143, Issue 2, 2004, Pages 99-105

  Fabbi, Patrizia ^a,b   Ghigliotti, Giorgio ^a   Brunelli, Claudio ^a   Balbi, Manrico ^a   Spallarossa, Paolo ^a   Rossettin, Pierfranco ^a   Barsotti, Antonio ^a   Odetti, Patrizio ^a   Garibaldi, Silvano ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b Lab di Biologia Cardiovascolare   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; LIPID PEROXIDE; MALONALDEHYDE; PROTHROMBIN; URIC ACID;

ADULT; AGED; ARTICLE; BLOOD; BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFLAMMATION; LIPID PEROXIDATION; MALE; METABOLIC DISORDER; ONSET AGE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; PREVALENCE; RISK FACTOR; THROMBOCYTE; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

EID: 1242272109     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lab.2003.10.009     Document Type: Article

References (58)

1. Sohal RS. The free radical hypothesis of aging: an appraisal of the current status. Aging (Milano) 1993;5:3-17.
2. Senti M, Tomas M, Vila J, Marrugat J, Elosua R, Sala J, et al. Relationship of age-related myocardial infarction risk and Gln/ Arg 192 variants of the human paraoxonasel gene: the REGICOR study. Atherosclerosis 2001;156:443-9.
3. Holvoet P, Collen D. Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis. Atherosclerosis 1998;137(suppl):S33-8.
4. Odetti P, Garibaldi S, Noberasco G, Aragno I, Valentini S, Traverso N, et al. Levels of carbonyl groups in plasma proteins of type 2 diabetes mellitus subjects. Acta Diabetol 1999;36:179-83.
5. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000;356:1213-18.
6. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:154-60.
7. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
8. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe UA. N Engl J Med 1994;331:417-24.
9. Li JJ, Jiang H, Huang CX, Fang CH, Tang QZ, Xia H, et al. Elevated level of plasma C-reactive protein in patients with UA: its relations with coronary stenosis and lipid profile. Angiology 2002;53:265-72.
10. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 2001;47:403-11.
11. Braunwald E. Unstable angina. A classification. Circulation 1989;80:410-4.
12. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988;296:313-6.
13. de Gaetano G. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001;357:101-5.
14. Young IS, Trimble ER. Measurement of malondialdehyde in plasma by high performance liquid chromatography with fluorimetric detection. Ann Clin Biochem 1991;28:504-8.
15. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995;96:2882-91.
16. Bilato C, Crow MT. Atherosclerosis and the vascular biology of aging. Aging (Milano) 1996;8:221-34.
17. Navab M, Fogelman AM, Berliner JA, Territo MC, Demer LL, Frank JS, et al. Pathogenesis of atherosclerosis. Am J Cardiol 1995;76(suppl):18C-23C.
18. Schwartz CJ, Valente AJ, Sprague EA. A modern view of atherogenesis. Am J Cardiol 1993;71(suppl):9B-14B.
19. Pratico D, Iuliano L, Mauriello A, Spagnoli L, Lawson JA, Rokach J, et al. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest 1997;100:2028-34.
20. Ruef J, Peter K, Nordt TK, Runge MS, Kubler W, Bode C. Oxidative stress and atherosclerosis: its relationship to growth factors, thrombus formation and therapeutic approaches. Thromb Haemost 1999;82(suppl 1):32-7.
21. Somers MJ, Harrison DG. Reactive oxygen species and the control of vasomotor tone. Curr Hypertens Rep 1999;1:102-8.
22. Somers MJ, Mavromatis K, Galis ZS, Harrison DG. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation 2000;101:1722-8.
23. Galle J, Heinloth A, Wanner C, Heermeier K. Dual effect of oxidized LDL on cell cycle in human endothelial cells through oxidative stress. Kidney Int 2001;78(suppl):S120-3.
24. Galle J, Heermeier K, Wanner C. Atherogenic lipoproteins, oxidative stress, and cell death. Kidney Int 1999;71(suppl):S62-5.
25. Galle J, Schneider R, Heinloth A, Wanner C, Galle PR, Conzelmann E, et al. Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: role of oxidative stress. Kidney Int 1999;55:1450-61.
26. Zafari AM, Ushio-Fukai M, Akers M, Yin Q, Shah A, Harrison DG, et al. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension 1998;32:488-95.
27. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-8.
28. 2 for platelet-derived growth factor signal transduction. Science 1995;270:296-9.
29. Patterson C, Ruef J, Madamanchi NR, Barry-Lane P, Hu Z, Horaist C, et al. Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin. Evidence that p47(phox) may participate in forming this oxidase in vitro and in vivo. J Biol Chem 1999;274:19814-22.
30. Maytin M, Leopold J, Loscalzo J. Oxidant stress in the vasculature. Curr Atheroscler Rep 1999;1:156-64.
31. Schieffer B, Luchtefeld M, Braun S, Hilfiker A, Hilfiker-Kleiner D, Drexler H. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res 2000;87:1195-201.
32. Shanmugasundaram KR, Srinivas K, Sundaram P, Sathyaraj D, Muthu R, Padma P, et al. Lipid peroxidation, antioxidant defences and red-cell membrane changes in relation to coronary risk index and symptomatic coronary heart disease. J Cardiovasc Risk 1995;2:551-61.
33. Kostner K, Hornykewycz S, Yang P, Neunteufl T, Glogar D, Weidinger F, et al. Is oxidative stress causally linked to unstable angina pectoris? A study in 100 CAD patients and matched controls. Cardiovasc Res 1997;36:330-6.
34. Yesilbursa D, Serdar Z, Dirican M, Serdar A, Gullulu S, Cordan J. Susceptibility of apolipoprotein B-containing lipoproteins to oxidation and antioxidant status in acute coronary syndromes. Clin Cardiol 2000;23:655-8.
35. Iqbal K, Rauoof MA, Mir MM, Tramboo NA, Malik JA, Naikoo BA, et al. Lipid peroxidation during acute coronary syndromes and its intensification at the time of myocardial ischemia reperfusion. Am J Cardiol 2002;89:334-7.
36. Yasunobu Y, Hayashi K, Shingu T, Yamagata T, Kajiyama G, Kambe M. Coronary atherosclerosis and oxidative stress as reflected by autoantibodies against oxidized low-density lipoprotein and oxysterols. Atherosclerosis 2001;155:445-53.
37. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001;21:844-8.
38. Belch JJ, Bridges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. Br Heart J 1991;65:245-8.
39. McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ. Evidence for oxidative stress in unstable angina. Br Heart J 1992;68:454-7.
40. Dubois-Rande JL, Artigou JY, Darmon JY, Habbal R, Manuel C, Tayarani I, et al. Oxidative stress in patients with unstable angina. Eur Heart J 1994;15:179-83.
41. Henkin Y, Crystal E, Goldberg Y, Friger M, Lorber J, Zuili I, et al. Usefulness of lipoprotein changes during acute coronary syndromes for predicting postdischarge lipoprotein levels. Am J Cardiol 2002;89:7-11.
42. Wachowicz B, Olas B, Zbikowska HM, Buczynski A. Generation of reactive oxygen species in blood platelets. Platelets 2002;13:175-82.
43. Aukrust P, Berge RK, Ueland T, Aaser E, Damas JK, Wikeby L, et al. Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol 2001;37:485-91.
44. Maseri A, Liuzzo G, Biasucci LM. Pathogenic mechanisms in unstable angina. Heart 1999;82(suppl 1):12-4.
45. Sorescu D, Weiss D, Lassegue B, Clempus RE, Szocs K, Sorescu GP, et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002;105:1429-35.
46. Cavallo-Perin P, Bergerone S, Gagnor A, Comune M, Giunti S, Cassader M, et al. Myocardial infarction before the age of 40 years is associated with insulin resistance. Metabolism 2001;50:30-5.
47. Krolewski AS, Kosinski EJ, Warram JH, Leland OS, Busick EJ, Asmal AC, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987;59:750-5.
48. McGill HC Jr, McMahan CA, Herderick EE, Zieske AW, Malcom GT, Tracy RE, et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002;105:2712-8.
49. Powell LA, Nally SM, McMaster D, Catherwood MA, Trimble ER. Restoration of glutathione levels in vascular smooth muscle cells exposed to high glucose conditions. Free Rad Biol Med 2001;31:1149-55.
50. Opara EC, Abdel-Rahman E, Soliman S, Kamel WA, Souka S, Lowe JE, et al. Depletion of total antioxidant capacity in type 2 diabetes. Metabolism 1999;48:1414-7.
51. Trevisan M, Browne R, Ram M, Muti P, Freudenheim J, Carosella AM, et al. Correlates of markers of oxidative status in the general population. Am J Epidemiol 2001;154:348-56.
52. Pleiner J, Schaller G, Mittermayer F, Bayerle-Eder M, Roden M, Wolzt M. FFA-induced endothelial dysfunction can be corrected by vitamin C. J Clin Endocrinol Metab 2002;87:2913-7.
53. Ames BN. Cathcart R, Schwiers E. Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981;78:685862.
54. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 2000;148:1319.
55. Rapola JM, Virtamo J, Ripatti S, Huttunen JK, Albanes D, Taylor PR, et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997;349:171520.
56. Stephens NG, Parsons A, Schofield PM. Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:7816.
57. Sozmen EY, Sozmen B, Girgin FK, Delen Y, Azarsiz E, Erdener D et al. Antioxidant enzymes and paraoxonase show a coactivity in preserving low-density lipoprotein from oxidation. Clin Exp Med 2001;1:1959.
58. Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000;20:51621.